CXCL12是2型糖尿病的潜在治疗点,这种糖尿病由慢性阻塞性肺病复杂化
Huaiwen Xu1, Li Weng2, Hong Xue2
1Department of Clinical Medicine, Fujian Medical University, Fuzhou 350122, China.
概括
CXCL12 是一种在2型糖尿病 (T2DM) 和慢性阻塞性肺病 (COPD) 中共享的致病基因. 用小分子药物向CXCL12,可能为复杂的T2DM和COPD病例提供新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 肺部病理学 肺部病理学
- 内分泌学 在内分泌学.
背景情况:
- 2型糖尿病 (T2DM) 和慢性阻塞性肺病 (COPD) 是具有复杂病理的流行疾病.
- 共同的病因因素和免疫路径可能会将T2DM和COPD联系起来.
- 了解这些共享机制对于开发有效的治疗策略至关重要.
研究的目的:
- 确定T2DM和COPD中常见的关键基因和免疫路径.
- 探索COPD复杂化的T2DM的潜在治疗点.
- 研究CXCL12在这两种疾病的发病过程中的作用.
主要方法:
- 来自GEO数据库的T2DM和COPD数据集的差异基因表达分析.
- 构建蛋白质-蛋白质相互作用网络以识别枢纽基因.
- 候选基因的验证,诊断准确性的评估 (ROC分析) 和与临床参数的相关性.
- 免疫细胞透分析 (CIBERSORT) 和药物基因相互作用分析 (DGIdb).
主要成果:
- 确定了175个常见的差异表达基因 (DEGs),这些基因在免疫和炎症途径中具有丰富作用.
- 鉴定出CXCL12是关键的目标基因,在T2DM和COPD中表达高,具有显著的诊断疗效.
- CXCL12表达与免疫细胞透和细胞因子-细胞因子受体相互作用有显著的相关性.
- 药物基因分析表明潜在的非细胞毒性小分子药物向CXCL12.
结论:
- CXCL12是COPD和T2DM中潜在的常见关键致病基因.
- 针对CXCL12的小分子药物代表了COPD复杂化的T2DM的有希望的治疗策略.
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
COPD: Pathogenesis and Clinical Features
228
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
228
COPD: Management Using Bronchodilators and Corticosteroids
177
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
177
Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Cystic Fibrosis: Management
139
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
139
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K


